Neuroscienze
In Johnson & Johnson stiamo costruendo una pipeline guidata dall’innovazione, che speriamo porti a terapie trasformative per un’ampia popolazione di pazienti con disturbi psichiatrici, neurodegenerativi e neurologici. Attraverso i progressi della scienza, un ampio spettro di competenze e partnership strategiche, miriamo a cambiare radicalmente le modalità di trattamento di queste patologie e a fare davvero la differenza per i pazienti e per la società.
È essenziale lavorare in collaborazione con le Associazioni di pazienti per guidare il cambiamento.
Oggi ci impegniamo a portare avanti una ricerca e uno sviluppo innovativi che risolvano le esigenze terapeutiche ancora insoddisfatte dei disturbi del sistema nervoso.
Referenze
[1]Deuschl G, et al. The burden of neurological diseases in Europe: An analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5(10):E551-E567.
[2]Open Access Government 2019. Tackling the growing burden of brain disorders in Europe. Available at: www.openaccessgovernment.org/brain-disorders-in-europe/72909/. Last accessed July 2023.
[3]GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018;392:1789-1858.
[4]PsychGuides.com. Neurological Problem Symptoms, Causes and Effects. Available at: www.psychguides.com/neurological-disorders/. Last accessed July 2023.
[5]WHO. Depression and other common mental disorders. Available at: WHO-MSD-MER-2017.2-eng.pdf Last accessed July 2023.
[6]WHO. Fact sheets. Depression. Available at www.who.int/news-room/fact-sheets/detail/depression. Last accessed July 2023.
[7]Machado-Viera R, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals. 2010;3(1):19–41.
[8]Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges and future directions. Patient Pref Adherence. 2012;6:369–388.
[9]Demyttenaere K & Van Duppen D. The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review. Int J Neuropsychopharmacol 2019;22(2):85–92.
[10]Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-17.
[11]Heerlein K, Perugi G, Otte C, et al. Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes. J Affect Disord. 2021;290:334-344.
CP-459038
Settembre 2024